Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP

Corbus Pharmaceuticals — Investor Presentation (November 2022)

32 slides from Corbus Pharmaceuticals's investor presentation, Nov 8, 2022

  1. Slide 1: Connecting Innovation to Purpose

    Connecting Innovation to Purpose Corporate Presentation October 2022 NASDAQ: CRBP • CorbusPharma.com • @CorbusPharma

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Co

  3. Slide 3: Corbus Pharmaceuticals

    Corbus Pharmaceuticals Immunology company focused on developing novel therapeutics through distinct platforms: Internal External Development Focus Partnering Programs Immuno-Oncology Endocannabinoid (IO) Portfolio Portfolio NASDAQ: CRBP • Anti-Integrins targeting • CB1 Inverse Agonist the TGFβ axis

  4. Slide 4: Growing a diversified pipeline

    Growing a diversified pipeline Compound Indications Preclinical Phase 1 Phase 2 Phase 3 Anti-Integrin Portfolio CRB-601 Solid Tumors Anti-⍺vβ8 mAb CRB-602 Anti-⍺vβ6/⍺vβ8 Solid Tumors / Fibrosis mAb Endocannabinoid Portfolio Lenabasum Dermatomyositis / Lupus CB2 Agonist CRB-913 Obesity / Metabolism C

  5. Slide 5: Focus on Immune Resistant Cancers for expansion of the Corbus pipeline

    Focus on Immune Resistant Cancers for expansion of the Corbus pipeline Mechanisms of Action in Focus Suppressors of 1 1 Immune Surveillance MDSC 2 Immune suppressive 2 Soluble factors/enzymes T-cells Seeking to bring in Soluble Factors other assets with Dysregulation of the potential to be 3 T-cell

  6. Slide 6: Immuno-Oncology Portfolio

    Immuno-Oncology Portfolio Innovative control of the TGFβ axis 6

  7. Slide 7: TGFβ plays a central role in immunoregulation and cancer

    TGFβ plays a central role in immunoregulation and cancer • TGFβ has been associated with immune cell exclusion in cancer Pro-inflammatory • Targeting TGFβ has been challenging Epithelium Tumor stroma – Local tumor versus systemic signaling may be key TGFβ Anti-inflammatory Resistant 7 Source: Dahman

  8. Slide 8: TGFβ predicts poor clinical outcomes in a subset of cancer patients

    TGFβ predicts poor clinical outcomes in a subset of cancer patients 1.0 Immunogenomic N = 8,461 cancers, multiple cell types subtypes in cancer Overall survival, % 0.8 C1 WOUND HEALING C2 INF-γ DOMINANT 0.6 C3 INFLAMMATORY C4 LYMPHOCYTE DEPLETED 0.4 C5 IMMUNOLOGICALLY QUIET C6 TGFβ DOMINANT TGFβ pre

  9. Slide 9: Successfully blocking TGFβ overcomes immune exclusion

    Successfully blocking TGFβ overcomes immune exclusion Isotype control Ab Anti-PD-L1 Ab Anti-TGFβ Ab Combination Stromal TGFβ signaling is a determinant of immuno-exclusion2 CD3 T Cells1 • An increase in CD3 immune cell infiltration is associated with the anti-PD/L-1 and anti-TGFβ antibody combinatio

  10. Slide 10: Targeting the integrin ⍺vβ8 represents a novel approach to regulating TGFβ

    Targeting the integrin ⍺vβ8 represents a novel approach to regulating TGFβ Recent experience with TGFβ1 TGFβ Pathway and Point of Therapeutic Intervention2 Investigational Blocking Novel point of therapeutic intervention TGFβ pathway Modality activation Compound of TGFβ Blocking the ⍺vβ8 activation

  11. Slide 11: CRB-601 binds at the interface between latent TGFβ and ⍺vβ8

    CRB-601 binds at the interface between latent TGFβ and ⍺vβ8 11

  12. Slide 12: CRB-601 binds to integrin ⍺vβ8 with high affinity and selectivity

    CRB-601 binds to integrin ⍺vβ8 with high affinity and selectivity Integrin Binding and Selectivity (Surface Plasmon Resonance) L-TGFb Binding Inhibition Test Integrin Antibody Dextran matrix Kd, nM Antibody avb1 avb3 avb5 avb6 avb8 mavb8 CRB-601 >200 >200 >200 >200 1.4 1.4 12 mCRB-601 : murine isoty

  13. Slide 13: CRB-601 enhances anti-PD-1 therapy in sensitive and resistant murine tumor models

    CRB-601 enhances anti-PD-1 therapy in checkpoint inhibition sensitive and resistant murine tumor models MC38 (Inflamed Tumor) EMT6 (Excluded Tumor) 4T1 (Desert Tumor) **** **** *** * *** *** * *** *** Checkpoint blockade sensitivity Sensitive Resistant CRB-601: 10 mg/kg BIW % TGI MC38 EMT6 4T1 Anti-

  14. Slide 14: CRB-601 enhances the impact of anti-PD-1 therapy on animals cured of tumor burden

    CRB-601 enhances the impact of anti-PD-1 therapy on the number of animals cured of their tumor burden MC38 Treatment CRB-601, 10 mg/kg, IP Immune inflamed implantation tumor Anti-PD-1 (RMP1-14), 10 mg/kg, IP n=10/group Days -11 0 3 7 Tumor volume = 200 mm3 (when treatment initiate) Isotype Anti-PD-1

  15. Slide 15: Tumor regression with CRB-601 and anti-PD-1 associated with T cell infiltration

    Tumor regression following treatment with CRB-601 and anti-PD-1 in MC38 tumors is associated with T cell infiltration and activation in tumors MC38 Treatment PD readouts CRB-601, 10 mg/kg, IP implantation Anti-PD-1 (RMP1-14), 10 mg/kg, IP Day-14 Day0 Day3 Day 7 Tumor volume = 250 mm3 (when treatment

  16. Slide 16: CRB-601 + anti-PD1 is associated with tumor-specific immune memory

    CRB-601 + anti-PD1 is associated with tumor-specific immune memory Treatment MC38 Day-8 MC38 SC SC Rechallenge CRB-601, IP (1,3 or10 mg/kg) survivors-grouped at re-challenge implantation Anti-PD-1 (RMP1-14), 10 mg/kg, IP Days 0 3 7 13 16 20 52 MC38, re-chellenge, 0.3 x 106/100ul, n=5 MC38, naive, 0.

  17. Slide 17: Blockade of ⍺vβ8 with anti-PD-1 increased TIL populations in EMT6 tumors

    Blockade of ⍺vβ8 in combination with anti-PD-1 increased TIL populations in immune excluded EMT6 tumors EMT6 orthotopic Treatment PD readouts CRB-601, 30 mg/kg, IP Tumor volume = 200 mm3 implantation Anti-PD-1, 10 mg/kg, IP (when treatment initiated) Days -14 0 3 6 10 CD4 T Cells CD8 T Cells *** ***

  18. Slide 18: Blockade of ⍺vβ8 with anti-PD-1 also increased NK and M1 macrophages

    Blockade of ⍺vβ8 in combination with anti-PD-1 also increased NK and M1 macrophages in immune excluded EMT6 tumors EMT6 orthotopic Treatment PD readouts CRB-601, 30 mg/kg, IP Tumor volume = 200 mm3 implantation Anti-PD-1 (RMP1-14), 10 mg/kg, IP (when treatment initiated) Days -14 0 3 6 10 Tumor Size

  19. Slide 19: Opportunities to differentiate the development of CRB-601

    Corbus may have significant opportunities to differentiate the development of CRB-601 Features of Example: Differentiation Strategic differentiation in PD-1 therapy IO TREATMENT Pre Clinical Phase 1 design • Modality • Ig Class • Route of administration SASANLIMAB • Clinical biomarkers • Indication

  20. Slide 20: Summary

    Summary CRB-601: • High affinity and high selectivity (low nM Kd) to avb8 • Inhibits tumor growth as a single agent and in combination with anti-PD-1 various tumor models. • Increases tumor-infiltrating T cells, NK cells and M1 polarized macrophages within EMT6 tumors. • On track for an IND in H1 20

  21. Slide 21: CRB-602 is a unique asset for fibrotic diseases and fibrotic cancers

    CRB-602 is a unique asset and may provide potential therapeutic benefit in fibrotic diseases and fibrotic cancers • CRB-602 is the only monoclonal antibody in development with dual ⍺vβ6 ⍺vβ8​ specificity for both ⍺vβ6 and ⍺vβ8​ Fibrosis, Cancer Cancer, inflammation and and • A rational approach to t

  22. Slide 22: CRB-913: 2nd Generation CB1 Inverse Agonist for Metabolic Diseases

    CRB-913: 2nd Generation CB1 Inverse Agonist for Metabolic Diseases Exploring Potential Partnership Opportunities 22

  23. Slide 23: Obesity is a global epidemic creating significant societal burden

    Obesity is a global epidemic creating significant societal burden with need for improvement on top of standard of care (incretin analogues, e.g. GLP-1) Dual-pharmacology holds great promise as a potential treatment 41% $2T option in obesity of worldwide adults annual global medical 0% projected to b

  24. Slide 24: CB1 Inverse Agonist targeting large metabolic disease market

    CB1 Inverse Agonist targeting large metabolic disease market Innovation • Rationally designed to achieve markedly reduced brain exposure to address psychiatric side effects with 1st generation CB1 inverse agonists – Potential to augment effects of GLP-1R agonists in diabetes and obesity – Combinatio

  25. Slide 25: CRB-913: a differentiated CB1 inverse agonist inducing weight loss

    CRB-913: a differentiated CB1 inverse agonist inducing weight loss in combination with semaglutide and tirzepatide Brain / Plasma Ratios Diet Induced Obesity (DIO) Mouse Model CRB-913 demonstrates a markedly reduced brain CRB-913 reduces weight both as single agent exposure vs. Rimonabant and in com

  26. Slide 26: Lenabasum: A Late-stage CB2 Agonist for Autoimmune Diseases

    Lenabasum: A Late-stage CB2 Agonist for Autoimmune Diseases Exploring Potential Partnership Opportunities 26

  27. Slide 27: Lenabasum is a late-stage clinical asset that presents significant opportunity

    Lenabasum is a late-stage clinical asset that presents significant opportunity OPPORTUNITY • First in class CB2 agonist • Capable of combining with existing SoC due to Non-immunosuppressive profile LEGEND • Large safety database CB • Clinical signals indicating potential for Receptor trial refinemen

  28. Slide 28: Lenabasum effects on skin in DM presents an opportunity for trial enrichment

    Lenabasum effects on skin in DM presents an opportunity for future trial enrichment Dermatomyositis (DM) is a heterogenous rare disease Clinical PoC1 characterized by a distinctive skin rash and muscle weakness2 Lenabasum Phase 2 in amyopathic (skin predominant) DM Phase 2 population 0.0 0.0 Δ CDASI

  29. Slide 29: Management Team

    Management Team Yuval Cohen, PhD Sean Moran, CPA, MBA Craig Millian, MBA Chief Executive Officer, Director Chief Financial Officer Chief Operating Officer Corbus co-founder and Chief Executive Corbus co-founder and Chief Financial Experience leading commercial Officer since 2014. Previously the Presid

  30. Slide 30: Board of Directors

    Board of Directors Amb. Alan Holmer Ret. Anne Altmeyer, PhD, MBA, MPH Avery W. (Chip) Catlin Yuval Cohen, PhD Chairman of the Board Director Director Chief Executive Officer, Director More than two decades of public service 20 years of experience advancing oncology More than 25 years of senior financi

  31. Slide 31: Investment Summary

    Investment Summary CRBP Focus on developing novel Ticker immuno-oncology therapeutics for serious cancers $74 Million Cash and investments as Advancing lead ⍺vβ8 integrin program to IND submission in H1-2023 of July 31, 2022 125.2M Common Shares Outstanding (145.2 M Fully Diluted) Engaging in busine

  32. Slide 32: > — , ce i A

    ik 3 > — , ce i A A . if a, ' JA : ae CORBUS \ PHARMACEUTICALS

Corbus Pharmaceuticals Holdings — Investor Presentation (November 2022) on 6ix